# Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes

Study · id `cardio:ct-nct07541456` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07541456](<https://clinicaltrials.gov/study/NCT07541456>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07541456

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT07541456. Randomized; single masking; primary purpose treatment. Start 2025-06-09 (actual); primary completion 2025-11-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT07541456, source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)
- Started: 2025-06-09 (actual) (ClinicalTrials.gov record NCT07541456, source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)
- Primary completion: 2025-11-08 (actual) (ClinicalTrials.gov record NCT07541456, source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)
- Completion: 2025-11-08 (actual) (ClinicalTrials.gov record NCT07541456, source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07541456, source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07541456-2026-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
- Acronym: EMPA-BP
- Condition: Type 2 Diabetes Mellitus
- Condition: Hypertension
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Metformin
- Lead sponsor: Dr. Zarmina Younes
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)

## Provenance

Content hash: f28e3f7aafb7f188936f745e051037b3c158ce75e553ea01f42b52e4b191361b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
